RHEACELL announces FDA approval for Phase 3 study in refractory, non-curable CVU
mehr
- Sprache:
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
Research Success in Rare Disease / RHEACELL receives positive signal for accelerated stem cell development program in rare ‚Butterfly Disease‘
mehrRHEACELL announces “First Patient In”: EB-Haus in Salzburg, Austria starts pivotal study for stem cell therapy for severe forms of Epidermolysis bullosa that is longed for by those affected
mehrStem cell therapy for “Butterfly disease” / RHEACELL receives ‘Partners in Progress Award’ from debra of America for Epidermolysis Bullosa research
mehr
1